VP, Business Development, Cardiovascular & Metabolism
Sarah Brennan heads the Cardiovascular & Metabolism Business Development Group at Johnson & Johnson. In this role, she leads Business Development Strategy in coordination with R&D and commercial leadership in support of the Janssen Cardiovascular, Metabolism and Retinal Therapeutic Disease Areas. Sarah is responsible for transactions, acquisitions, scientific licensing and alliance management.
Sarah has over 20 years of industry experience spanning across Pharmaceuticals and Medical Devices, as well as different functions including R&D, Sales and Marketing. Prior to Business Development, Sarah led the Janssen U.S. Metabolics Business as Vice President, Sales & Marketing where she had responsibility for INVOKANA® marketing, Sales Learning & Development, and Primary Care Sales.
Previously, Sarah was Vice President, Change Leadership & Business Transformation leading the Johnson & Johnson Medical Devices change strategy. She also served as World Wide Vice President for Ethicon Biosurgery, with responsibility for pipeline strategy and global commercialization of our portfolio - inclusive of medical devices, biologics and combination products.
Sarah began her Johnson & Johnson career at Cordis Corporation, where she held positions of increasing responsibility. She also held additional roles at Ethicon and served as Director of Marketing at Janssen, leading the development of the U.S. launch strategy for bapineuzumab IV for the treatment of Alzheimer’s disease.
Sarah received a Bachelor of Science in Biology from Dickinson College in Carlisle, PA.